Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Product: | Diclofenac Devatis |
| Active Ingredient: | Diclofenac sodium 1mg/mL |
| Dosage Form: | Eye drops, solution |
| New Zealand Sponsor: | Devatis Limited |
| Manufacturer: | Deva Holding AS, Kartepe, Turkey |
| Product: | Imbruvica |
| Active Ingredient: | Ibrutinib 140mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
| Manufacturer: | Catalent CTS Inc, Missouri, United States of America |
| Product: | Imbruvica |
| Active Ingredient: | Ibrutinib 280mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
| Manufacturer: | Catalent CTS Inc, Missouri, United States of America |
| Product: | Imbruvica |
| Active Ingredient: | Ibrutinib 420mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
| Manufacturer: | Catalent CTS Inc, Missouri, United States of America |
| Product: | Imbruvica |
| Active Ingredient: | Ibrutinib 560mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
| Manufacturer: | Catalent CTS Inc, Missouri, United States of America |
Dated this 6th day of April 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).